Welcome to GSK’s product website

Here you will find information about GSK’s medicines and vaccines

I’m a UK healthcare professional

Important notice: this site is intended for UK healthcare professionals. By entering this site, you are confirming that you are a UK healthcare professional. This site may contain promotional information.

I’m a member of the UK public

This site is intended for members of the UK public, patients and their carers.

M.C. Last updated: March 2018. UK/COM/0106/15(2)

M.C. Last updated: March 2018. UK/COM/0106/15(2)

menu_icon

Relvar Ellipta is indicated for the regular
treatment of patients with asthma ≥12 years
where use of a combination product (longacting
ß2-agonist and inhaled corticosteroid) is
appropriate:

  • Patients not adequately controlled with
    inhaled corticosteroids and ‘as-needed’
    inhaled short-acting ß2-agonists
  • Patients already adequately controlled
    on both inhaled corticosteroids and long
    acting ß2-agonists1
Samples are only available to order for patients already adequately controlled on ICS/LABA
Order a Sample

Improved asthma control

Relvar Ellipta was superior to ICS/LABAs
in helping more patients improve asthma
control in everyday clinical practice in the
Salford Lung Study2

In the Salford Lung Study, an open label, effectiveness RCT
comparing Relvar with usual care in over 4,000 patients, the
most commonly used ICS/LABAs in the ITT population were3:


  • Seretide (fluticasone propionate/salmeterol) 30%
  • Symbicort (budesonide/formoterol) 15%
  • Fostair (beclometasone/formoterol) 12%

Relvar Ellipta asthma control

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back